JAK3 Antibody (A1-14-16): sc-56921

JAK3 Antibody (A1-14-16) is a mouse monoclonal IgG2a antibody that detects JAK3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. JAK3, or Janus kinase 3, plays a crucial role in the signaling pathways of the immune system, particularly in the lympho-hematopoietic system, where JAK3 regulates various cellular functions downstream of activated cytokine receptors. JAK3 is primarily located in the cytoplasm, where JAK3 interacts with cytokine receptor-associated proteins, facilitating the phosphorylation of Stat transcription factors. This interaction is vital for the transduction of signals that lead to the transcription of genes involved in immune responses, including those that promote cell proliferation, differentiation, and survival. The proper functioning of JAK3 is essential for maintaining a balanced immune response, and dysregulation of JAK3 activity can lead to autoimmune diseases and other inflammatory conditions. By targeting JAK3, researchers can explore therapeutic strategies aimed at modulating immune responses, making anti-JAK3 antibody (A1-14-16) an invaluable tool for studying immune signaling pathways and developing anti-inflammatory therapies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

JAK3 Antibody (A1-14-16) References:

1. The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines.  |  Higuchi, M., et al. 2002. J Virol. 76: 455-9. PMID: 11739714
2. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.  |  Losdyck, E., et al. 2015. J Biol Chem. 290: 29022-34. PMID: 26446793
3. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.  |  Qiu, Q., et al. 2019. Expert Rev Clin Pharmacol. 12: 547-554. PMID: 31059310
4. Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.  |  Su, W., et al. 2022. Bioorg Med Chem Lett. 64: 128680. PMID: 35306167
5. Molecular docking analysis of Indole based diaza-sulphonamides with JAK-3 protein.  |  Nautiyal, M., et al. 2023. Bioinformation. 19: 74-78. PMID: 37720295
6. New JAK3-INSL3 Fusion Transcript-An Oncogenic Event in Cutaneous T-Cell Lymphoma.  |  Velatooru, LR., et al. 2023. Cells. 12: PMID: 37830594
7. In vitro and in vivo modelling of mutant JAK3/STAT5 signaling in leukemia.  |  Omari, SA., et al. 2023. Heliyon. 9: e22085. PMID: 38053908
8. Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter.  |  Hossain, MM., et al. 2024. J Transl Med. 22: 370. PMID: 38637842
9. Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.  |  Yamaguchi, Y., et al. 2024. Arch Dermatol Res. 316: 478. PMID: 39023568
10. Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata.  |  Nunez, M., et al. 2024. Expert Opin Drug Metab Toxicol. 20: 1023-1036. PMID: 39252171

The preferred JAK3 antibody is JAK3 Antibody (B-12): sc-6932.